{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:02:08Z","timestamp":1793289728949,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014421","name":"EA Pharma Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014421","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Translational Autoimmunity"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jtauto.2025.100283","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T23:11:52Z","timestamp":1742512312000},"page":"100283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["A placebo-controlled Phase 2 trial of E6011, anti-human fractalkine monoclonal antibody, in primary biliary cholangitis"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6358-5283","authenticated-orcid":false,"given":"Atsushi","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4489-9102","authenticated-orcid":false,"given":"Masanori","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Namisaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikio","family":"Zeniya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Ido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Yoshiji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromasa","family":"Ohira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9498-2886","authenticated-orcid":false,"given":"Yuko","family":"Kakuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Umeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2762-7192","authenticated-orcid":false,"given":"Yuki","family":"Kamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Higashine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichiro","family":"Hojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4022-1962","authenticated-orcid":false,"given":"Toshio","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsu","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuni","family":"Nakanuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohito","family":"Tsubouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtauto.2025.100283_bib1","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(24)01303-5","article-title":"Primary biliary cholangitis","volume":"404","author":"Tanaka","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jtauto.2025.100283_bib2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41575-019-0226-7","article-title":"Primary biliary cholangitis: pathogenesis and therapeutic opportunities","volume":"17","author":"Gulamhusein","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.jtauto.2025.100283_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40265-023-01979-1","article-title":"New therapies on the horizon for primary biliary cholangitis","volume":"84","author":"Tanaka","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.jtauto.2025.100283_bib4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jtauto.2025.100283_bib5","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jtauto.2025.100283_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-021-10276-6","article-title":"APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis","volume":"16","author":"You","year":"2022","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jtauto.2025.100283_bib7","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis","volume":"71","author":"Harms","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jtauto.2025.100283_bib8","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"Obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jtauto.2025.100283_bib9","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jtauto.2025.100283_bib10","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","article-title":"Fibrates for Itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial","volume":"160","author":"de Vries","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jtauto.2025.100283_bib11","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jhep.2021.04.010","article-title":"Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis","volume":"75","author":"Tanaka","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jtauto.2025.100283_bib12","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and safety of elafibranor in primary biliary cholangitis","volume":"390","author":"Kowdley","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jtauto.2025.100283_bib13","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A phase 3 trial of seladelpar in primary biliary cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jtauto.2025.100283_bib14","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2177\/jsci.28.131","article-title":"Fractalkine and inflammatory diseases","volume":"28","author":"Imai","year":"2005","journal-title":"Jpn. J. Clin. Immunol."},{"key":"10.1016\/j.jtauto.2025.100283_bib15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s41232-016-0017-2","article-title":"Therapeutic intervention of inflammatory\/immune diseases by inhibition of the fractalkine (CX3CL1)-CX3CR1 pathway","volume":"36","author":"Imai","year":"2016","journal-title":"Inflamm. Regen."},{"key":"10.1016\/j.jtauto.2025.100283_bib16","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1749-6632.2009.04738.x","article-title":"Chemokines as novel therapeutic targets for inflammatory bowel disease","volume":"1173","author":"Nishimura","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jtauto.2025.100283_bib17","doi-asserted-by":"crossref","first-page":"7825","DOI":"10.4049\/jimmunol.0803627","article-title":"Role of CX3CL1\/fractalkine in osteoclast differentiation and bone resorption","volume":"183","author":"Koizumi","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.jtauto.2025.100283_bib18","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2147\/ITT.S277991","article-title":"Emerging role of fractalkine in the treatment of rheumatic diseases","volume":"9","author":"Tanaka","year":"2020","journal-title":"ImmunoTargets Ther."},{"key":"10.1016\/j.jtauto.2025.100283_bib19","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/hep.20582","article-title":"Fractalkine and CX3CR1 are involved in the recruitment of intraepithelial lymphocytes of intrahepatic bile ducts","volume":"41","author":"Isse","year":"2005","journal-title":"Hepatology"},{"issue":"suppl-2","key":"10.1016\/j.jtauto.2025.100283_bib20","first-page":"A732","volume":"114","author":"Nishimura","year":"2017","journal-title":"Journal of Japanese Society of Gastroenterology"},{"key":"10.1016\/j.jtauto.2025.100283_bib21","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/jcph.1361","article-title":"Pharmacokinetics, Pharmacodynamics, and safety of E6011, a novel humanized antifractalkine (CX3CL1) monoclonal antibody: a randomized, double-blind, placebo-controlled single-ascending-dose study","volume":"59","author":"Tabuchi","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jtauto.2025.100283_bib22","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1080\/14397595.2017.1337056","article-title":"Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1\/2 study on rheumatoid arthritis","volume":"28","author":"Tanaka","year":"2018","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.jtauto.2025.100283_bib23","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/art.41555","article-title":"Efficacy and safety of E6011, an anti-fractalkine monoclonal antibody, in patients with active rheumatoid arthritis with inadequate response to methotrexate: results of a randomized, double-blind, placebo-controlled phase II study","volume":"73","author":"Tanaka","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jtauto.2025.100283_bib24","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1080\/14397595.2020.1868675","article-title":"A phase 2 study of E6011, an anti-Fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs","volume":"31","author":"Tanaka","year":"2021","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.jtauto.2025.100283_bib25","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1111\/jgh.15463","article-title":"Phase 1 study on the safety and efficacy of E6011, antifractalkine antibody, in patients with Crohn's disease","volume":"36","author":"Matsuoka","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jtauto.2025.100283_bib26","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jtauto.2025.100283_bib27","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid","volume":"130","author":"Par\u00e9s","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jtauto.2025.100283_bib28","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/jclinpath-2014-202417","article-title":"Canals of Hering loss relates to the progression of the histological stages of primary biliary cirrhosis","volume":"68","author":"Kakuda","year":"2015","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.jtauto.2025.100283_bib29","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/hep.23637","article-title":"American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis","volume":"52","author":"Silveira","year":"2010","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"10.1016\/j.jtauto.2025.100283_bib30","first-page":"71","article-title":"Guidelines for the management of primary biliary cirrhosis","volume":"44","year":"2014","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.jtauto.2025.100283_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-31063-8","article-title":"Symptoms and health-related quality of life in Japanese patients with primary biliary cholangitis","volume":"8","author":"Yagi","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jtauto.2025.100283_bib32","first-page":"1817","article-title":"Proposal of novel staging and grading system of primary biliary cirrhosis","volume":"108","author":"Nakanuma","year":"2011","journal-title":"Journal of Japanese Society of Gastroenterology"},{"key":"10.1016\/j.jtauto.2025.100283_bib33","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jtauto.2025.100283_bib34","article-title":"New risk factor for progressive multifocal leukoencephalopathy (PML) associated with tysabri (natalizumab)","year":"2012","journal-title":"Safety Announcement"},{"key":"10.1016\/j.jtauto.2025.100283_bib35","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.4049\/jimmunol.164.8.4313","article-title":"CX3C-chemokine, fractalkine-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and -independent mechanisms","volume":"164","author":"Goda","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.jtauto.2025.100283_bib36","series-title":"Group of \u201cInvestigational Research Prion Diseases and Late Viral Infections\u201d for MHLW Scientific Research Funded Research Project for the Conquest of Refractory Diseases","year":"2013"},{"key":"10.1016\/j.jtauto.2025.100283_bib37","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/hep4.1170","article-title":"NI-0801, an anti-chemokine (C-X-C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid","volume":"2","author":"De Graaf","year":"2018","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.jtauto.2025.100283_bib38","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/hep.28359","article-title":"Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: a proof-of-concept study","volume":"64","author":"Hirschfield","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jtauto.2025.100283_bib39","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jaut.2019.04.005","article-title":"Therapeutic trials of biologics in primary biliary cholangitis: an open label study of abatacept and review of the literature","volume":"101","author":"Bowlus","year":"2019","journal-title":"J. Autoimmun."}],"container-title":["Journal of Translational Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589909025000188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589909025000188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T22:56:58Z","timestamp":1750892218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589909025000188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":39,"alternative-id":["S2589909025000188"],"URL":"https:\/\/doi.org\/10.1016\/j.jtauto.2025.100283","relation":{},"ISSN":["2589-9090"],"issn-type":[{"value":"2589-9090","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A placebo-controlled Phase 2 trial of E6011, anti-human fractalkine monoclonal antibody, in primary biliary cholangitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Translational Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtauto.2025.100283","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100283"}}